Congress May Set a $2K Medicare Drug Plan Patient Spending Cap

News November 03, 2021 at 01:40 PM
Share & Print

Negotiators in Washington are trying to set a $2,000 annual limit on what Medicare Part D prescription drug plan enrollees pay out of pocket for covered medications.

If successful, the effort to add a drug spending cap could remove a big source of uncertainty from Medicare and retirement planning clients' spending projections.

President Joe Biden's administration announced Tuesday that the drug spending cap is now part of the "Build Back Better" framework.

The framework is the base for an effort by the Biden administration to develop a social spending package that can win enough votes both from progressive Democrats in the House and from centrist Democrats such as Kyrsten Sinema of Arizona and Joe Manchin of West Virginia in the Senate, to get through Congress.

The Medicare Part D Plan Catastrophic Threshold

Medicare Part D drug plans now pay 95% of the cost when patients who do not qualify for the Medicare low-income enrollee subsidy go over a catastrophic drug spending threshold. This year, the catastrophic spending provision will kick in when patients spend more than $6,550 of their own cash on covered drugs.

From 2010 through 2019, Part D plan enrollees spent an average of about $2.6 billion per year on drug costs not covered by their Part D plans, according to an analysis from the Henry J. Kaiser Family Foundation.

Enrollees spent an average of about $990 million per year out of pocket on drugs for prescriptions filled after those enrollees had crossed the catastrophic drug coverage threshold.

About 3.6 million patients crossed the catastrophic threshold for at least one year between 2010 and 2019, the Kaiser analysts estimate.

Lawmakers and regulators created that patient cost-sharing structure in an effort to encourage patients to do their part to help reduce unnecessary use of expensive drugs. In practice, patients often run into the catastrophic drug spending threshold when they are coping with devastating, potentially fatal illnesses, such as hard-to-control diabetes, kidney failure or cancer.

Other Build Back Better Framework Changes

Officials said the latest version of the framework also includes provisions that would:

• Put a $35 monthly cap on what people with diabetes pay for insulin.

• "Lower seniors' cost-sharing for all types of drugs."

• Impose a tax penalty on drug companies that raise drug prices faster than the rate of inflation.

• Create a "clearly defined negotiation process" for Medicare administrators and drug manufacturers. This provision appears to be a compromise between lawmakers who want Medicare to be an aggressive drug price negotiator and those who might want to keep the current curbs on Medicare's ability to negotiate with the manufacturers. The provision would let Medicare negotiate prices for just 10 drugs per year in 2023, and 20 drugs per year in 2025 and later years.

What This Means for Medicare Plan Agents

If the new Medicare drug plan spending cap proposal takes effect roughly as described, it could make Medicare drug plans more attractive to consumers.

At eHealth, a health insurance web broker, the estimated lifetime value of commissions for a Medicare Part D enrollee was $216 in the third quarter.

That was considerably lower than the $938 lifetime value estimate for a Medicare supplement insurance enrollee, but it was comparable to the $286 lifetime value of commissions for a person who bought individual major medical coverage through an Affordable Care Act public exchange, and higher than the $88 lifetime value of commissions for a person who bought dental coverage.

(Image: Shutterstock)

NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Related Stories

Resource Center